Skip to main content
Erschienen in: Community Mental Health Journal 6/2010

01.12.2010 | Original Paper

Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida’s Medicaid Program

verfasst von: Robert J. Constantine, Ross Andel, Rajiv Tandon

Erschienen in: Community Mental Health Journal | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

We studied trends in antipsychotic polypharmacy over a 4 year period in order to see if a change occurred when a statewide quality improvement program aimed at reducing the practice was implemented. Antipsychotic polypharmacy prevalence rates were calculated for eight 6-month periods for enrollees with schizophrenia and schizoaffective disorder and for those with all other diagnoses. Prevalence increased from 1/2003 to 12/2004 and then declined for 4 successive 6 month periods beginning in the 1/2005–6/05 period when the program began. Piecewise linear regression results for both diagnostic groups confirmed that the change in the likelihood of antipsychotic polypharmacy during the four 6 month periods before program implementation were significantly different than during the four 6 month periods following implementation. While it is impossible to control for the effects of all variables in evaluating the impact of any system wide intervention the data suggest that the program did help to reduce the use of antipsychotic polypharmacy.
Literatur
Zurück zum Zitat American Psychiatric Association. (2004). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(Supplement), 1–56. American Psychiatric Association. (2004). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(Supplement), 1–56.
Zurück zum Zitat Barbui, C., Nose, M., Mazzi, M. A., Thornicroft, G., Schene, A., Becker, T., et al. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21(6), 355–362.CrossRefPubMed Barbui, C., Nose, M., Mazzi, M. A., Thornicroft, G., Schene, A., Becker, T., et al. (2006). Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. International Clinical Psychopharmacology, 21(6), 355–362.CrossRefPubMed
Zurück zum Zitat Biancosino, B., Barbui, C., Marmai, L., Doná, S., & Grassi, L. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. International Clinical Psychopharmacology, 20(6), 305–309.CrossRefPubMed Biancosino, B., Barbui, C., Marmai, L., Doná, S., & Grassi, L. (2005). Determinants of antipsychotic polypharmacy in psychiatric inpatients: A prospective study. International Clinical Psychopharmacology, 20(6), 305–309.CrossRefPubMed
Zurück zum Zitat Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007). Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharmacy World & Science, 29(3), 126–130.CrossRef Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007). Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. Pharmacy World & Science, 29(3), 126–130.CrossRef
Zurück zum Zitat Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. American Journal of Psychiatry, 161(4), 700–706.CrossRefPubMed Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. American Journal of Psychiatry, 161(4), 700–706.CrossRefPubMed
Zurück zum Zitat Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., et al. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatric Services, 57(8), 1094–1101.CrossRefPubMed Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K., et al. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatric Services, 57(8), 1094–1101.CrossRefPubMed
Zurück zum Zitat Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy. Schizophrenia Bulletin, 28(1), 75–84.PubMed Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy. Schizophrenia Bulletin, 28(1), 75–84.PubMed
Zurück zum Zitat Clinical practice guidelines. (2005). Treatment of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 50:(13 Suppl 1), 7S–57S. Clinical practice guidelines. (2005). Treatment of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 50:(13 Suppl 1), 7S–57S.
Zurück zum Zitat Constantine, R. J., Richard, S., Surlea, R., et al. (2006). Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis and Therapeutics Reports, 4(1), 5–11.CrossRef Constantine, R. J., Richard, S., Surlea, R., et al. (2006). Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis and Therapeutics Reports, 4(1), 5–11.CrossRef
Zurück zum Zitat Correll, C. U. (2008). Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? American Society of Clinical Psychopharmacology, 69(4), 674–675. Correll, C. U. (2008). Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? American Society of Clinical Psychopharmacology, 69(4), 674–675.
Zurück zum Zitat Elie, D., Poirier, M., Chianetta, J., Durand, M., Gregoire, C., & Grignon, S. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 1–8. Elie, D., Poirier, M., Chianetta, J., Durand, M., Gregoire, C., & Grignon, S. (2009). Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology, 1–8.
Zurück zum Zitat Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry [Electronic Resource], 5(1), 26.CrossRef Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry [Electronic Resource], 5(1), 26.CrossRef
Zurück zum Zitat Freudenreich, O., & Goff, D. C. (2002). Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(5), 323–330.CrossRefPubMed Freudenreich, O., & Goff, D. C. (2002). Antipsychotic combination therapy in schizophrenia: A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(5), 323–330.CrossRefPubMed
Zurück zum Zitat Ganesan, S., Taylor, R., Rabheru, K., Forbes, I., Dumontet, J., & Procyshyn, R. M. (2008). Antipsychotic polypharmacy does not increase the risk for side effects. Schizophrenia Research, 98(1), 323–324.CrossRefPubMed Ganesan, S., Taylor, R., Rabheru, K., Forbes, I., Dumontet, J., & Procyshyn, R. M. (2008). Antipsychotic polypharmacy does not increase the risk for side effects. Schizophrenia Research, 98(1), 323–324.CrossRefPubMed
Zurück zum Zitat Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. The Journal of Clinical Psychiatry, 65(10), 1377–1388.CrossRefPubMed Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. The Journal of Clinical Psychiatry, 65(10), 1377–1388.CrossRefPubMed
Zurück zum Zitat Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services, 58(7), 1007–1010.CrossRefPubMed Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services, 58(7), 1007–1010.CrossRefPubMed
Zurück zum Zitat Goff, D. C., & Freudenreich, O. (2004). Focus on polypharmacy in schizophrenia: does anyone truly benefit? The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7(2), 109–111. Goff, D. C., & Freudenreich, O. (2004). Focus on polypharmacy in schizophrenia: does anyone truly benefit? The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 7(2), 109–111.
Zurück zum Zitat Goren, J. L., Parks, J. J., Ghinassi, F. A., Milton, C. G., Oldham, J. M., Hernandez, P., et al. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission Journal on Quality and Patient Safety, 34(10), 571–582.PubMed Goren, J. L., Parks, J. J., Ghinassi, F. A., Milton, C. G., Oldham, J. M., Hernandez, P., et al. (2008). When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Joint Commission Journal on Quality and Patient Safety, 34(10), 571–582.PubMed
Zurück zum Zitat Hardin, J., & Hilbe, J. (2002). Generalized estimating equations. Danvers, MA: CRC Press.CrossRef Hardin, J., & Hilbe, J. (2002). Generalized estimating equations. Danvers, MA: CRC Press.CrossRef
Zurück zum Zitat Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., Saitoh, O., Iwase, M., Kajimoto, O., Takeda, M., Okabe, S., & Kunugi, H. (2006). Antipsychotic medication and cognitive function in schizophrenia. Hori, H., Noguchi, H., Hashimoto, R., Nakabayashi, T., Omori, M., Takahashi, S., Tsukue, R., Anami, K., Hirabayashi, N., Harada, S., Saitoh, O., Iwase, M., Kajimoto, O., Takeda, M., Okabe, S., & Kunugi, H. (2006). Antipsychotic medication and cognitive function in schizophrenia.
Zurück zum Zitat Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. The British Journal of Psychiatry: The Journal of Mental Science, 187, 243–247.CrossRef Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: psychiatrists’ perceptions of antipsychotic drug prescription. The British Journal of Psychiatry: The Journal of Mental Science, 187, 243–247.CrossRef
Zurück zum Zitat Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122–127.CrossRefPubMed Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122–127.CrossRefPubMed
Zurück zum Zitat Kreyenbuhl, J., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research, 84(1), 90–99.CrossRefPubMed Kreyenbuhl, J., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2006). Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research, 84(1), 90–99.CrossRefPubMed
Zurück zum Zitat Lelliott, P., Paton, C., Harrington, M., Konsolaki, M., Sensky, T., & Okocha, C. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26(11), 411–414.CrossRef Lelliott, P., Paton, C., Harrington, M., Konsolaki, M., Sensky, T., & Okocha, C. (2002). The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin, 26(11), 411–414.CrossRef
Zurück zum Zitat Lewis, S. B. T. D. L., et al. (2006). Randomized controlled trial of effect of prescription of clozapine verses other second-generation antipsychotic drugs in treatment resistant schizophrenia. Schizophrenis Bulletin, 32(4), 715–723.CrossRef Lewis, S. B. T. D. L., et al. (2006). Randomized controlled trial of effect of prescription of clozapine verses other second-generation antipsychotic drugs in treatment resistant schizophrenia. Schizophrenis Bulletin, 32(4), 715–723.CrossRef
Zurück zum Zitat Loosbrock, D. L., Zhao, Z., Johnstone, B. M., & Morris, L. S. (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. The Journal of Mental Health Policy and Economics, 6(2), 67–75.PubMed Loosbrock, D. L., Zhao, Z., Johnstone, B. M., & Morris, L. S. (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. The Journal of Mental Health Policy and Economics, 6(2), 67–75.PubMed
Zurück zum Zitat McCue, R. E., Waheed, R., & Urcuyo, L. (2003). Polypharmacy in patients with schizophrenia. The Journal of Clinical Psychiatry, 64(9), 984–989.CrossRefPubMed McCue, R. E., Waheed, R., & Urcuyo, L. (2003). Polypharmacy in patients with schizophrenia. The Journal of Clinical Psychiatry, 64(9), 984–989.CrossRefPubMed
Zurück zum Zitat McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19–32.CrossRefPubMed McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80(1), 19–32.CrossRefPubMed
Zurück zum Zitat Miller, A. L., & Craig, C. S. (2002). Combination antipsychotics: pros, cons, and questions. Schizophrenia Bulletin, 28(1), 105–109.PubMed Miller, A. L., & Craig, C. S. (2002). Combination antipsychotics: pros, cons, and questions. Schizophrenia Bulletin, 28(1), 105–109.PubMed
Zurück zum Zitat Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a Multistate medicaid population, 1998–2003. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, 29(1), 183–195. Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a Multistate medicaid population, 1998–2003. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy, 29(1), 183–195.
Zurück zum Zitat National Institute for Clinical Excellence. (2002). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care: Clinical Guideline 1. National Institute for Clinical Excellence. (2002). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care: Clinical Guideline 1.
Zurück zum Zitat Procyshyn, R. M., Kennedy, N. B., Tse, G., & Thompson, B. (2001). Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. The Canadian Journal of Psychiatry/La Revue Canadienne De Psychiatrie, 46(4), 334–339. Procyshyn, R. M., Kennedy, N. B., Tse, G., & Thompson, B. (2001). Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. The Canadian Journal of Psychiatry/La Revue Canadienne De Psychiatrie, 46(4), 334–339.
Zurück zum Zitat Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Trivedi, M. H., et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. The Journal of Clinical Psychiatry, 64(4), 357–369.CrossRefPubMed Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Trivedi, M. H., et al. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. The Journal of Clinical Psychiatry, 64(4), 357–369.CrossRefPubMed
Zurück zum Zitat Sernyak, M. J., & Rosenheck, R. (2004). Clinicians’ reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry, 65(12), 1597–1600.CrossRefPubMed Sernyak, M. J., & Rosenheck, R. (2004). Clinicians’ reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry, 65(12), 1597–1600.CrossRefPubMed
Zurück zum Zitat Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(2), 178–183.CrossRefPubMed Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., et al. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British Journal of Clinical Pharmacology, 58(2), 178–183.CrossRefPubMed
Zurück zum Zitat Stahl, S. M. (2004). Focus on Antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology, 7(2), 113–116.CrossRefPubMed Stahl, S. M. (2004). Focus on Antipsychotic polypharmacy: Evidence-based prescribing or prescribing-based evidence? International Journal of Neuropsychopharmacology, 7(2), 113–116.CrossRefPubMed
Zurück zum Zitat Suzuki, T., Uchida, H., Tanaka, K. F., Tomita, M., Tsunoda, K., Nomura, K., et al. (2003). Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 18(6), 323–329.CrossRefPubMed Suzuki, T., Uchida, H., Tanaka, K. F., Tomita, M., Tsunoda, K., Nomura, K., et al. (2003). Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. International Clinical Psychopharmacology, 18(6), 323–329.CrossRefPubMed
Zurück zum Zitat Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., et al. (2008). Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology: Clinical and Experimental, 23(6), 455–463.CrossRef Suzuki, T., Uchida, H., Watanabe, K., Nakajima, S., Nomura, K., Takeuchi, H., et al. (2008). Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology: Clinical and Experimental, 23(6), 455–463.CrossRef
Zurück zum Zitat Tapp, A. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(4), 574a.CrossRef Tapp, A. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(4), 574a.CrossRef
Zurück zum Zitat Tranulis, C. (2008). Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety, 31(1), 7–20.CrossRefPubMed Tranulis, C. (2008). Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safety, 31(1), 7–20.CrossRefPubMed
Zurück zum Zitat Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., & Allen, R. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs. Current Medical Research and Opinion, 23(10), 2567–2576.CrossRefPubMed Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., & Allen, R. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs. Current Medical Research and Opinion, 23(10), 2567–2576.CrossRefPubMed
Zurück zum Zitat Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.CrossRefPubMed Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry, 173, 325–329.CrossRefPubMed
Zurück zum Zitat Weissman, E. M. (2002). Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophrenia Bulletin, 28(1), 31–42.PubMed Weissman, E. M. (2002). Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophrenia Bulletin, 28(1), 31–42.PubMed
Zurück zum Zitat Zhu, B., Ascher-Svanum, H., Faries, D. E., Correll, C. U., & Kane, J. M. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8, 19.CrossRefPubMed Zhu, B., Ascher-Svanum, H., Faries, D. E., Correll, C. U., & Kane, J. M. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8, 19.CrossRefPubMed
Metadaten
Titel
Trends in Adult Antipsychotic Polypharmacy: Progress and Challenges in Florida’s Medicaid Program
verfasst von
Robert J. Constantine
Ross Andel
Rajiv Tandon
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Community Mental Health Journal / Ausgabe 6/2010
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI
https://doi.org/10.1007/s10597-009-9288-2

Weitere Artikel der Ausgabe 6/2010

Community Mental Health Journal 6/2010 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.